Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04985825

Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma — I-PACE  

Cutaneous Squamous Cell Carcinoma Clinical Trial

Official title:
Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)

Clinical Trial Summary

This study will evaluate the anti-tumor activity, safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of imgatuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR) with enhanced antibody-dependent cellular cytotoxicity (ADCC) in patients with advanced cutaneous squamous cell carcinoma (CSCC). Quality of life of patients treated with imgatuzumab will also be assessed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04985825
Study type Interventional
Source Centessa Pharmaceuticals plc
Contact
Status Withdrawn
Phase Phase 2
Start date December 16, 2021
Completion date August 17, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05377905 - Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC) Phase 1/Phase 2
Recruiting NCT05888844 - A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04050436 - Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer Phase 2
Recruiting NCT05574101 - A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer Phase 2
Completed NCT04616196 - Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Phase 1/Phase 2
Recruiting NCT05108090 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT04975152 - Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Phase 1
Completed NCT01500954 - Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma N/A
Suspended NCT04916002 - A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer Phase 2
Active, not recruiting NCT04339062 - Cemiplimab in AlloSCT/SOT Recipients With CSCC Phase 1/Phase 2
Recruiting NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Recruiting NCT04664582 - Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck N/A
Not yet recruiting NCT06384820 - Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) Phase 2
Terminated NCT04596033 - TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy Phase 1
Active, not recruiting NCT06046625 - Needs and Preferences of Patients With Head-neck Cutaneous SCC